Increasing evidence indicates that the gut microbiome modulates brain development and function across the lifespan. This pinpoints the microbiota-gut-brain axis as a potential target for influencing mood and behaviour, such as anxiety and depression, as well as preventing or treating brain-related diseases, including Parkinson’s disease, Alzheimer’s disease, schizophrenia and autism. Currently, one of the biggest challenges is the translation of these insights into the clinical context. Winclove is proud to be initiating partner of MIND, MOOD & MICROBES – the International Conference on Microbiota-Gut-Brain Axis – . The conference wll take place for the second time on 17-19 January in Amsterdam and will bring together academics, healthcare professionals, and industry partners from diverse and complimentary fields of expertise to accelerate the translation of research breakthroughs into professional and clinical practice.